Most insurance plans do not cover GLP-1 medications for weight loss without a type 2 diabetes diagnosis, and even then coverage varies
Medicare is effectively testing whether obesity medications can become a benefit for its broad base of participants, but because this program operates outside normal Part D coverage and its $50 payments do not count toward beneficiaries annual out-of-pocket totals, access after 2027 will depend on further revisions to either continue the program in its current form or make a more substantial effort to integrate it into existing Medicare services, Alex Beene, a financial literacy instructor for the University of Tennessee at Martin, told Newsweek
The number of individual lawsuits against Novo Nordisk continues to rise since the first lawsuit was filed in August 2023 by Jaclyn Bjorklund against Novo Nordisk and Eli Lilly (the manufacturer of Mounjaro)
Retatrutide activates the glucagon receptor in addition to the GIP and GLP-1 receptors that tirzepatide targets
Gargs studies evaluated the real-world use of GLP-1s prescribed to people with type 1 diabetes at the Barbara Davis Center
high blood pressure, high cholesterol)
